CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
增强抗白血病免疫治疗的策略
英文原题：Strategies to enhance anti-leukaemia immunotherapy.
查看英文原题
Strategies to enhance anti-leukaemia immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
急性髓系白血病（AML）在异基因造血细胞移植（allo-HCT）出现之前是一种无法治愈的疾病，而allo-HCT已被证明是一种有效的细胞免疫治疗方法。然而，allo-HCT具有重大副作用，疾病复发是常见的并发症。新型免疫疗法旨在降低毒性并增强allo-HCT的抗白血病活性。基因工程方法的技术进步使得能够产生强效的免疫治疗活性，同时限制毒性。针对AML脆弱性的小分子药物的生物学驱动应用有望增强抗白血病免疫治疗。对这些方法进行广泛的临床前测试对于降低毒性以及为未来临床测试寻找理想的联合伙伴至关重要。
展开英文摘要原文
Acute myeloid leukaemia (AML) was an incurable disease prior to allogeneic haematopoietic cell transplantation (allo-HCT), which was proven to be a potent cellular immunotherapy-approach.
However, allo-HCT has major side effects, with disease relapse presenting as a frequent complication. Novel immunotherapies aim to reduce toxicity and increase the anti-leukaemia activity of allo-HCT. Technological advancements in genetic engineering approaches enable potent immunotherapeutic activity while limiting toxicities.
A biology-driven application of small molecules that target AML vulnerabilities holds promise to enhance anti-leukaemia immunotherapy. Extensive preclinical testing of these approaches is essential to reduce toxicity and to find the ideal combination partners for future clinical testing.
论文信息
- 作者
- Lysandrou M、Zeiser R
- 第一作者单位
- Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center University Freiburg, Albert-Ludwigs University of Freiburg, Germany.Germany
- 通讯作者单位
- Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center University Freiburg, Albert-Ludwigs University of Freiburg, Germany. Electronic address: robert.zeiser@uniklinik-freiburg.de.Germany
- 文献类型
- 综述
- 期刊
- Current opinion in pharmacology2025 Jun
- 原文标识
- PubMed 40267742 · DOI 10.1016/j.coph.2025.102525